Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

80.300
+2.5503.28%
Volume:2.57M
Turnover:207.08M
Market Cap:24.01B
PE:-36.03
High:83.250
Open:78.750
Low:77.000
Close:77.750
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.53
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.229
ROE:21.49%
ROA:-8.24%
PB:5.14
PE(LYR):-36.03
PS:24.65

Loading ...

Jinrui Securities Maintains Buy Rating on KEYMED BIO-B, Citing Validation of Long-Acting AD Drug Value by Major Pharma Deal

Stock News
·
Jun 23

Movement Alert|CanNova-B Rises 5.38% in Regular Trading, AbbVie 10.9 Billion Dollar Apogee Acquisition Validates Long-Acting AD Product Value

Market Focus
·
Jun 23

Keymed Bio-B Shares Surge Over 6% in Morning Trading Following AbbVie's Major Acquisition

Stock News
·
Jun 23

KEYMED BIO-B Surges Nearly 6% on Completion of Ouro Medicines Acquisition Deal and Receipt of $257 Million Initial Payment

Stock News
·
Jun 12

Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close

MT Newswires Live
·
Jun 05

KEYMED BIO-B Receives Initial $257 Million Payment from Sale of Ouro Medicines Stake

Stock News
·
Jun 05

Keymed Biosciences receives US$257.00 million from Ouro Medicines divestment; Gilead–Lakefront alliance to steer CM336/OM336 development

Bulletin Express
·
Jun 05

Keymed Biosciences: No Share Capital Changes in May 2026, Public Float Remains Sufficient

Bulletin Express
·
Jun 02

Movement Alert|CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan

Market Focus
·
May 29

Industrial Securities Initiates Coverage on KEYMED BIO-B with 'Buy' Rating, Citing Pipeline Value Reassessment

Stock News
·
May 18

Keymed Bio Monthly Return: Share Capital Steady at 298.74 Million; Public Float Meets 25% Threshold

Bulletin Express
·
May 06

Keymed Biosciences Sets 26 June 2026 for AGM; Proposes Director Re-election, EY Reappointment and General Mandates

Bulletin Express
·
Apr 29

Keymed Biosciences Inc.2025年业绩亮相:营收7.163亿元创新高,多元化研发助力商业化拓展

Bulletin Express
·
Apr 29

Keymed Biosciences publishes 2025 annual report

Reuters
·
Apr 29

Keymed Biosciences announces annual general meeting

Reuters
·
Apr 29

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

Keymed Biosciences issues supplemental disclosure on Ouro Medicines stake disposal

Reuters
·
Apr 15

KEYMED BIO-B Surges Nearly 8% in Afternoon Trading Following Gilead's Acquisition of Ouro

Stock News
·
Apr 15

KEYMED BIO-B (02162) Rises Nearly 6% Again as CMG313 Sales Accelerate and Global Value Pathway Clarifies

Stock News
·
Apr 02

KEYMED BIO-B Reports Unchanged Share Capital and Confirms Public Float Compliance for March 2026

Bulletin Express
·
Apr 01